GlassScriptPhysician profile
Dorothy A Gioia
NPI 1013433176
$2,896.89
in general payments reported to CMS, 2019-2025
33 companies · $650 in 2025
The $650 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $659 · 2023: $476 · 2024: $870 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.68 | 2022-2025 | |
| Novo Nordisk INC | $271.33 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $222.48 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.39 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $138.57 | 2021-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $138.29 | 2021-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $115.71 | 2021-2025 | Eohilia, Entyvio |
| Novartis Pharmaceuticals Corporation | $86.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $79.32 | 2022-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $77.70 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $74.04 | 2023-2025 | General - Pain Management |
| Axsome Therapeutics, INC. | $58.14 | 2023-2024 | Auvelity |
| Avanir Pharmaceuticals, INC. | $55.47 | 2022 | |
| Pfizer INC. | $42.45 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $41.66 | 2024-2025 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $39.48 | 2021-2022 | |
| Genzyme Corporation | $31.79 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.68 | 2021-2022 | |
| Ardelyx, INC. | $26.53 | 2024 | Ibsrela |
| Amgen INC. | $24.07 | 2025 | Evenity |
| Ironwood Pharmaceuticals, INC | $22.94 | 2024 | |
| Seqirus USA INC | $19.88 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Celltrion USA INC. | $19.74 | 2024 | Vegzelma |
| Ibsa Pharma INC. | $19.37 | 2021 | |
| Aimmune Therapeutics, INC. | $18.85 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.56 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.75 | 2022 | |
| Abbott Laboratories | $17.17 | 2025 | Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $17.10 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $16.42 | 2025 | Lagevrio |
| Currax Pharmaceuticals LLC | $15.69 | 2022 | |
| Genentech USA, INC. | $15.64 | 2021 | |
| Hologic Sales and Service, LLC | $14.86 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Gioia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.